PDT Partners’s AstraZeneca AZN Stock Holding History

PDT Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-172,317	Closed	-$11M	–	1263
2015 Q2	$11M	Buy	+172,317	New	+$11.8M	0.29%	67
2014 Q4	–	Sell	-5,206	Closed	-$372K	–	651
2014 Q3	$372K	Sell	5,206 -6,916	-57%	-$506K	0.01%	1038
2014 Q2	$901K	Buy	+12,122	New	+$876K	0.02%	744
2013 Q3	–	Sell	-245,207	Closed	-$11.6M	–	1495
2013 Q2	$11.6M	Buy	+245,207	New	+$12.5M	0.28%	67

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PDT Partners's AZN Position: Q3 2015 in Review

PDT Partners sold out of AstraZeneca (AZN) in Q3 2015, closing a stake of 172,317 shares — an estimated $11M sold.

PDT Partners first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $11.6M in Q2 2013. 371 funds tracked by Wall St. Rank hold AZN as of Q3 2015.

PDT Partners reported no remaining AstraZeneca position as of Q3 2015 after selling out during the quarter.
PDT Partners sold 172,317 AstraZeneca shares in Q3 2015, an estimated $11M.
PDT Partners first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
PDT Partners's AstraZeneca position peaked at $11.6M in Q2 2013.
371 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2015.

Based on PDT Partners's 13F filing for Q3 2015, filed 16 Nov 2015.